Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
J Subst Abuse Treat
; 127: 108460, 2021 08.
Article
em En
| MEDLINE
| ID: mdl-34134878
ABSTRACT
Direct acting antiviral (DAA) treatment has made the elimination of hepatitis C virus (HCV) a realisable global public health goal and people who inject drugs are a key target population. This study investigates barriers and enablers to DAA treatment of HCV in general practice settings in Australia, from the patient perspective. Semi-structured interviews were conducted with 28 patients; of these patients, seventeen participants were currently on opioid agonist therapy, and four were currently injecting drugs. Thematic data analysis was undertaken and a personal, provider and systems framework was used to describe the barriers and enablers to DAA treatment. Results suggest a range of initiatives are required to support the uptake of DAA in general practice settings. These include the provision of formalised peer information and support, and increasing the accessibility of blood tests and liver assessment on-site. Further, there remains a need to address stigma and discrimination affecting people who inject drugs in community healthcare settings.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Acesso_medicamentos_insumos_estrategicos
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Preparações Farmacêuticas
/
Abuso de Substâncias por Via Intravenosa
/
Hepatite C
/
Hepatite C Crônica
/
Medicina Geral
Tipo de estudo:
Qualitative_research
Limite:
Humans
País/Região como assunto:
Oceania
Idioma:
En
Revista:
J Subst Abuse Treat
Ano de publicação:
2021
Tipo de documento:
Article